Meridian Bioscience Inc. (VIVO) News
Filter VIVO News Items
VIVO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest VIVO News From Around the Web
Below are the latest news stories about MERIDIAN BIOSCIENCE INC that investors may wish to consider to help them evaluate VIVO as an investment opportunity.
Meridian Biosciences Stock: Why I Moved On But May Go Back In (NASDAQ:VIVO)Meridian Biosciences released an update saying it set the closing date for its merger on Jan. 31. Read more on this deal and implications for investors. |
Meridian Bioscience stock gains after announcing Jan. 31 closing date for saleMeridian Bioscience (VIVO) rose 8% after it said its planned sale to SD Biosensor, SJL Partners is expected to close on Jan |
Meridian Bioscience sets closing date for $1.53 billion dealOn Monday, officials with Meridian Bioscience Inc., a provider of diagnostic testing and life science raw materials, announced their pending $1.53 billion merger with two South Korean-based firms will close Jan. 31. |
Meridian Bioscience Announces Anticipated Closing Date of the Pending MergerMeridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has entered into a side letter with the buyer, setting the closing date of Meridian's pending merger for January 31, 2023. |
Meridian Bioscience Fiscal Q4 Revenues Fall 14 Percent, Full-Year Revenues Grow 5 PercentThe firm''s diagnostics segment revenues climbed 14 percent year over year in fiscal Q4, while life sciences revenues were down 37 percent. |
Meridian Bioscience Non-GAAP EPS of $0.21, revenue of $65.67MMeridian Bioscience press release (VIVO): Q4 Non-GAAP EPS of $0.21.Revenue of $65.67M (-13.8% Y/Y).Diagnostics segment net revenues increased 14% year-over-year to $39.2… |
Meridian Bioscience (VIVO) Q4 Earnings Surpass EstimatesMeridian Bioscience (VIVO) delivered earnings and revenue surprises of 33.33% and 2.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2022 OPERATING RESULTSMeridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2022. |
BellRing Brands (BRBR) Beats Q4 Earnings EstimatesBellRing Brands (BRBR) delivered earnings and revenue surprises of 6.90% and 6.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
4 Stocks That Can Turn $100,000 Into $500,000 by the Time You RetireMost investors would like to see their stock portfolio grow significantly, especially if they have quite a few years left until retirement. Alphabet (NASDAQ: GOOG), Vertex Pharmaceuticals (NASDAQ: VRTX), Eli Lilly and Company (NYSE: LLY), and Meridian Bioscience (NASDAQ: VIVO) all show solid potential to grow your investments significantly. Alphabet's stock has risen 105% over the past five years. |